Intermediate for Carfilzomib. Carfilzomib (trade name: Kyprolis) is an anti-cancer drug acting as a selective proteasome inhibitor. Carfilzomib has been approved by the U.S Food and Drug Administration on July 20, 2012.
Product Name: (4-Morpholinyl)acetic acid trifluoroacetic acid salt
CAS Number: 163587-52-8
Molecular Weight:  259.1817
Molecular Formula:  C8H12F3NO5
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.